Thompson Street Capital Partners' portfolio company Tropichem Research Labs, LLC acquires TetraGenx

On March 21, 2018, Tropichem Research Labs, LLC acquired TetraGenx.

Tropichem is a portfolio company of St. Louis-based private equity firm Thompson Street Capital Partners. Tropichem develops, manufactures and packages animal care, personal care and household and industrial products out of its facility in Florida.

Montreal-based TetraGenx is a leading independent animal health contract development and manufacturing organization. TetraGenx specializes in complex drug product formulation development to create innovative pharmaceutical, over-the-counter and nutraceutical veterinary pharma products. Its services encompass four main categories, including product development (pre-formulation, formulation and analytical development), analytical testing, manufacturing and ancillary support services.

McCarthy Tétrault LLP advised Tropichem and Thompson Street Capital Partners with a team led by Patrick M. Shea and that included Cristel Chabot-Lapointe, Sarah Cote-Hamel, Thomas Etienne, Sven Milelli, Maureen Gillis, Suzanne Elie and Donna LeClair (Corporate and M&A); Marie-France Gagnon and Eve Tessier (Debt Financing); Véronique Wattiez Larose, Lisa Melanson, Vincent Yip, Benjamin Lai and Marissa Caldwell (Intellectual Property and Regulatory); Christian Meighen, Nicolas Désy, Angelo Discepola, Andrew Haikal and Alexandra Carbone (Tax); Diana Theophilopoulos (Labour and Employment); Madeleine Renaud (Competition and Foreign Investment Review); Dominique Amyot-Bilodeau (Environmental); Randy Bauslaugh and Kelleher Lynch (Employee Benefits); and Mary Pagonis and Mahsa Khoshbin (Real Estate).